Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021
Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021
HempFusion CBD and Probulin Probiotics Partner with Two-Time Olympic Gold Medalist and Five-Time World Champion, Kaillie Humphries May 27, 2021 Life Science
HempFusion Signs Definitive Agreement to Acquire Leading CBD Brand Sagely Naturals May 25, 2021 Life Science
HempFusion Signs Definitive Agreement to Acquire Pioneering CBD Brand Apothecanna May 17, 2021 Life Science
HempFusion Accelerates International Sales with United Arab Emirates Reopening May 12, 2021 Life Science
HempFusion Wellness Inc. To Report First Quarter 2021 Earnings and Host Conference Call on May 17, 2021 May 11, 2021 Life Science
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis Apr 30, 2021 Life Science
Rethinking the approach to diagnose cancer | VolitionRx Limited Apr 30, 2021 Life Science, Technology
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering Apr 26, 2021 Life Science, Technology
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list Apr 23, 2021 Life Science, Technology
